Alkermes (ALKS) Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Alkermes delivered a mixed fourth quarter for 2025, beating on revenue while falling well short on the bottom line, as the expiration of its lucrative INVEGA SUSTENNA royalty continued to weigh on results. The Dublin-based biopharmaceutical company p… Read more Alkermes delivered a mixed fourth quarter for 2025, beating on revenue while falling well short on the bottom line, as the expiration of its lucrative INVEGA SUSTENNA royalty continued to weigh on results. The Dublin-based biopharmaceutical company posted Q4 revenue of $384.55 million, edging past the $381.30 million consensus by 0.85%, though that figure still represented a 10.6% decline from the year-ago period when royalty income padded the top line. Earnings per share came in at $0.29, missing the $0.41 analyst consensus by 29.27%, with GAAP net income falling sharply to $49.34 million from $146.50 million in Q4 2024. Bright spots included LYBALVI, whose revenues of $94.14 million grew 22% year over year, helping proprietary product net sales climb to $315.49 million. The bigger story, however, is the February 2026 close of the $2.3 billion Avadel Pharmaceuticals acquisition, which adds narcolepsy drug LUMRYZ to the portfolio and underpins 2026 revenue guidance of $1.73 billion to $1.84 billion, even as acquisition-related charges are expected to push the company to a GAAP net loss of $115 million to $135 million next year.